Multicentre, Double-blind, Randomised, Placebo-controlled Study in Four Parallel Groups of PD Patients Treated With Standard-release Levodopa/Carbidopa 100/25 mg (Sinemet) or Levodopa/Benserazide 100/25 mg (Madopar/Restex) and With Motor Fluctuations ("Wearing-off" Phenomenon)
Latest Information Update: 06 Apr 2015
At a glance
- Drugs Opicapone (Primary)
- Indications Parkinson's disease
- Focus Therapeutic Use
- Sponsors Bial
- 07 Jan 2015 According to the ClinicalTrials.gov record the primary endpoint changed to Cmax and Tmax.
- 20 Jun 2013 Results presented at the 17th International Congress of Parkinson's Disease and Movement Disorders.
- 12 Apr 2012 New trial record